Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Ophthalmic Topical Therapeutics Market

ID: MRFR/HC/18447-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026

US Ophthalmic Topical Therapeutics Market Research Report: By Product Type (Artificial Tears, Anti-allergy, Antibiotic Drops, Anti-Inflammatory, Antiglaucoma, Others), By Disease Type (Dry Eye, Eye Allergy, Glaucoma, Eye Infection, Retinal Disorders, Uveitis, Others), By Dosage Form (Eye Drops, Gels, Ointments, Others) and By Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, Others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Ophthalmic Topical Therapeutics Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Billion)
  49.     4.1.1 Anti-inflammatory
  50.     4.1.2 Antibiotic
  51.     4.1.3 Antiviral
  52.     4.1.4 Antiglaucoma
  53.     4.1.5 Lubricants
  54.   4.2 Healthcare, BY Formulation Type (USD Billion)
  55.     4.2.1 Solutions
  56.     4.2.2 Suspensions
  57.     4.2.3 Ointments
  58.     4.2.4 Gels
  59.     4.2.5 Emulsions
  60.   4.3 Healthcare, BY Route of Administration (USD Billion)
  61.     4.3.1 Topical
  62.     4.3.2 Intravitreal
  63.     4.3.3 Subconjunctival
  64.     4.3.4 Periocular
  65.     4.3.5 Systemic
  66.   4.4 Healthcare, BY Therapeutic Area (USD Billion)
  67.     4.4.1 Glaucoma
  68.     4.4.2 Dry Eye Disease
  69.     4.4.3 Infectious Diseases
  70.     4.4.4 Allergic Conjunctivitis
  71.     4.4.5 Retinal Disorders
  72.   4.5 Healthcare, BY End User (USD Billion)
  73.     4.5.1 Hospitals
  74.     4.5.2 Ophthalmology Clinics
  75.     4.5.3 Homecare Settings
  76.     4.5.4 Pharmacies
  77.     4.5.5 Research Institutions
  78. 5 SECTION V: COMPETITIVE ANALYSIS
  79.   5.1 Competitive Landscape
  80.     5.1.1 Overview
  81.     5.1.2 Competitive Analysis
  82.     5.1.3 Market share Analysis
  83.     5.1.4 Major Growth Strategy in the Healthcare
  84.     5.1.5 Competitive Benchmarking
  85.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  86.     5.1.7 Key developments and growth strategies
  87.       5.1.7.1 New Product Launch/Service Deployment
  88.       5.1.7.2 Merger & Acquisitions
  89.       5.1.7.3 Joint Ventures
  90.     5.1.8 Major Players Financial Matrix
  91.       5.1.8.1 Sales and Operating Income
  92.       5.1.8.2 Major Players R&D Expenditure. 2023
  93.   5.2 Company Profiles
  94.     5.2.1 Allergan (US)
  95.       5.2.1.1 Financial Overview
  96.       5.2.1.2 Products Offered
  97.       5.2.1.3 Key Developments
  98.       5.2.1.4 SWOT Analysis
  99.       5.2.1.5 Key Strategies
  100.     5.2.2 Bausch + Lomb (US)
  101.       5.2.2.1 Financial Overview
  102.       5.2.2.2 Products Offered
  103.       5.2.2.3 Key Developments
  104.       5.2.2.4 SWOT Analysis
  105.       5.2.2.5 Key Strategies
  106.     5.2.3 Regeneron Pharmaceuticals (US)
  107.       5.2.3.1 Financial Overview
  108.       5.2.3.2 Products Offered
  109.       5.2.3.3 Key Developments
  110.       5.2.3.4 SWOT Analysis
  111.       5.2.3.5 Key Strategies
  112.     5.2.4 Novartis (CH)
  113.       5.2.4.1 Financial Overview
  114.       5.2.4.2 Products Offered
  115.       5.2.4.3 Key Developments
  116.       5.2.4.4 SWOT Analysis
  117.       5.2.4.5 Key Strategies
  118.     5.2.5 Santen Pharmaceutical (JP)
  119.       5.2.5.1 Financial Overview
  120.       5.2.5.2 Products Offered
  121.       5.2.5.3 Key Developments
  122.       5.2.5.4 SWOT Analysis
  123.       5.2.5.5 Key Strategies
  124.     5.2.6 Aerie Pharmaceuticals (US)
  125.       5.2.6.1 Financial Overview
  126.       5.2.6.2 Products Offered
  127.       5.2.6.3 Key Developments
  128.       5.2.6.4 SWOT Analysis
  129.       5.2.6.5 Key Strategies
  130.     5.2.7 Horizon Therapeutics (IE)
  131.       5.2.7.1 Financial Overview
  132.       5.2.7.2 Products Offered
  133.       5.2.7.3 Key Developments
  134.       5.2.7.4 SWOT Analysis
  135.       5.2.7.5 Key Strategies
  136.     5.2.8 Ocular Therapeutix (US)
  137.       5.2.8.1 Financial Overview
  138.       5.2.8.2 Products Offered
  139.       5.2.8.3 Key Developments
  140.       5.2.8.4 SWOT Analysis
  141.       5.2.8.5 Key Strategies
  142.     5.2.9 EyePoint Pharmaceuticals (US)
  143.       5.2.9.1 Financial Overview
  144.       5.2.9.2 Products Offered
  145.       5.2.9.3 Key Developments
  146.       5.2.9.4 SWOT Analysis
  147.       5.2.9.5 Key Strategies
  148.   5.3 Appendix
  149.     5.3.1 References
  150.     5.3.2 Related Reports
  151. 6 LIST OF FIGURES
  152.   6.1 MARKET SYNOPSIS
  153.   6.2 US MARKET ANALYSIS BY APPLICATION
  154.   6.3 US MARKET ANALYSIS BY FORMULATION TYPE
  155.   6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  156.   6.5 US MARKET ANALYSIS BY THERAPEUTIC AREA
  157.   6.6 US MARKET ANALYSIS BY END USER
  158.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  159.   6.8 RESEARCH PROCESS OF MRFR
  160.   6.9 DRO ANALYSIS OF HEALTHCARE
  161.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  162.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  163.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  164.   6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  165.   6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  166.   6.15 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
  167.   6.16 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
  168.   6.17 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  169.   6.18 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  170.   6.19 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
  171.   6.20 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
  172.   6.21 HEALTHCARE, BY END USER, 2024 (% SHARE)
  173.   6.22 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
  174.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  175. 7 LIST OF TABLES
  176.   7.1 LIST OF ASSUMPTIONS
  177.     7.1.1
  178.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  179.     7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  180.     7.2.2 BY FORMULATION TYPE, 2026-2035 (USD Billion)
  181.     7.2.3 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
  182.     7.2.4 BY THERAPEUTIC AREA, 2026-2035 (USD Billion)
  183.     7.2.5 BY END USER, 2026-2035 (USD Billion)
  184.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  185.     7.3.1
  186.   7.4 ACQUISITION/PARTNERSHIP
  187.     7.4.1

US Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

  • Anti-inflammatory
  • Antibiotic
  • Antiviral
  • Antiglaucoma
  • Lubricants

Healthcare By Formulation Type (USD Billion, 2026-2035)

  • Solutions
  • Suspensions
  • Ointments
  • Gels
  • Emulsions

Healthcare By Route of Administration (USD Billion, 2026-2035)

  • Topical
  • Intravitreal
  • Subconjunctival
  • Periocular
  • Systemic

Healthcare By Therapeutic Area (USD Billion, 2026-2035)

  • Glaucoma
  • Dry Eye Disease
  • Infectious Diseases
  • Allergic Conjunctivitis
  • Retinal Disorders

Healthcare By End User (USD Billion, 2026-2035)

  • Hospitals
  • Ophthalmology Clinics
  • Homecare Settings
  • Pharmacies
  • Research Institutions

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓